source
- Genmab faces steep revenue cliff as Darzalex patents expire, eyes pivotal Epkinly readoutGenmab relies heavily on Darzalex, a cancer drug co‑developed with Johnson & Johnson, which currently provides about 90% of the company’s sales. U.S. patents for Darzalex are set to expire in 2029,…
- Rapport Therapeutics reports Phase 2 success for RAP-219 in bipolar mania trialRapport Therapeutics announced that its lead candidate RAP-219 met the primary endpoint in a Phase 2 study of adults with acute bipolar mania. The double-blind trial enrolled 253 patients and meas…